Current Opinion in Lipidology volume 27, issue 6, P579-584 2016 DOI: 10.1097/mol.0000000000000354 View full text
|
|
Share
Steven E. Gryn, Robert A. Hegele

Abstract: Statins will remain the backbone of lipid-lowering therapy, although several novel oral agents are promising. The common theme across drugs in development is the demonstration of good lipid-lowering effect, although lacking cardiovascular outcomes data, which will likely be necessary before any of them, can be recommended or approved for widespread use.